Publication | Open Access
Up-regulation of Plasma Hexosylceramide (d18
15
Citations
24
References
2016
Year
ImmunologyHepatitis BPathologyChronic Hepatitis CAutoimmune Liver DiseaseInflammationPlasma HexcerHepatic DisordersViral HepatitisClinical EpidemiologyHepatotoxicityCell SignalingPlasma HexosylceramideLiver PhysiologyHepatology InflammationPharmacologyHepatitis DPlasma SphingolipidsCytokineSignal TransductionHepatologyHepatitis CHepatitisLiver DiseaseImmunosuppressionLiverMedicine
The aim of the present study was to explore the relationship between plasma sphingolipids and hepatitis C virus (HCV) replication in chronic hepatitis C (CHC) patients.A cohort of 120 treatment-naïve CHC patients was included. Liver biopsies and the Scheuer scoring system were used to assess hepatic inflammatory activity. Blood biochemical indicators, HCV-RNA load, and immunological markers were also measured. Forty-four plasma sphingolipids were identified and quantified using high-performance liquid chromatography-tandem mass spectrometry.The hexosylceramide (HexCer) (d18:1/18:1) level was significantly different between patients with a low HCV load (<10 IU/mL) and a high HCV load (≥10 IU/mL), and it was positively correlated with the HCV-RNA load (r = 0.337, P = 0.001) in CHC patients. Additionally, the plasma HexCer (d18:1/18:1) level (odds ratio 1.302, 95% confidence interval 1.129-1.502) was an independent factor for a high HCV-RNA load. For patients with hepatic inflammation grade ≤2 or HCV genotype 2, HexCer (d18:1/18:1) was independently related to a high HCV-RNA load.Plasma HexCer (d18:1/18:1) might be involved in the high viral replication level in chronic HCV infection, especially for CHC patients with genotype 2.
| Year | Citations | |
|---|---|---|
Page 1
Page 1